

Amit G Singal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2956222/publications.pdf>

Version: 2024-02-01

418
papers

24,324
citations

10351

72
h-index

10424

139
g-index

425
all docs

425
docs citations

425
times ranked

20231
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors for HCC in contemporary cohorts of patients with cirrhosis. <i>Hepatology</i> , 2023, 77, 997-1005.	3.6	36
2	Correlation of LI-RADS 3 or 4 Observations with Histopathologic Diagnosis in Patients with Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1351-1353.e2.	2.4	3
3	Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 670-680.e18.	2.4	22
4	Clinical Outcomes of Patients With Suspicious (LI-RADS 4) Liver Observations. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1649-1651.e2.	2.4	11
5	Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1091-1093.e3.	2.4	15
6	Racial and Ethnic Disparities in Barriers to Care in Patients with Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1094-1096.e2.	2.4	22
7	Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 988-994.e2.	2.4	7
8	Depression and Anxiety Are Common Among Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 194-203.e1.	2.4	23
9	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	2.4	15
10	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 9-18.	2.4	58
11	Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1739-1747.	2.4	19
12	Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 204-215.e6.	2.4	31
13	Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1795-1802.e2.	2.4	6
14	A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1188-e1191.	2.4	6
15	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	6.1	62
16	Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 953-955.e2.	2.4	21
17	Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1561-1569.e4.	2.4	52
18	A Conceptual Model for Implementation and Evaluation of Interventions Across the Hepatocellular Carcinoma Care Continuum. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1174-1176.	2.4	4

#	ARTICLE	IF	CITATIONS
19	Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. <i>Hepatology Communications</i> , 2022, 6, 223-236.	2.0	8
20	Decreasing Trend of Serum Î±-Fetoprotein Level in Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1177-1179.e4.	2.4	13
21	Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer. <i>Gut</i> , 2022, 71, 1332-1339.	6.1	32
22	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 173-182.e7.	2.4	62
23	Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective. <i>Liver Transplantation</i> , 2022, 28, 422-436.	1.3	11
24	Rational HCC screening approaches for patients with NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 195-201.	1.8	47
25	Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1157-e1169.	2.4	12
26	Racial and Ethnic Disparities in Germline Genetic Testing of Patients With Young-Onset Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 353-361.e3.	2.4	30
27	Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e267-e288.	2.4	32
28	GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. <i>Hepatology</i> , 2022, 75, 541-549.	3.6	70
29	Increasing Incidence Rates of Colorectal Cancer at Ages 50â€“54 Years. <i>Gastroenterology</i> , 2022, 162, 964-965.e3.	0.6	14
30	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1289-1299.	3.6	26
31	Racial, Ethnic, and Socioeconomic Disparities in Curative Treatment Receipt and Survival in Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2022, 6, 1186-1197.	2.0	19
32	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	4.2	29
33	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
34	Colorectal Cancer Screening and Yield in a Mailed Outreach Program in a Safety-Net Healthcare System. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4403-4409.	1.1	5
35	Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in highâ€“risk patients. <i>Liver International</i> , 2022, 42, 2080-2092.	1.9	28
36	Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?. <i>Hepatology</i> , 2022, 75, 740-753.	3.6	26

#	ARTICLE	IF	CITATIONS
37	Incidence of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2022, 162, 1772-1774.	0.6	2
38	Understanding Compliance, Practice Patterns, and Barriers Among Gastroenterologists and Primary Care Providers Is Crucial for Developing Strategies to Improve Screening for Barrett's Esophagus. <i>Gastroenterology</i> , 2022, 162, 1568-1573.e4.	0.6	7
39	REPLY: "Look for a physical health status surrogate in hepatocellular carcinoma: Have we found the holy grail?" <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	2.4	0
40	The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon With Acceptable Outcomes. <i>Transplantation Direct</i> , 2022, 8, e1297.	0.8	2
41	Cost Effectiveness of Mailed Outreach Programs for Colorectal Cancer Screening: Analysis of a Pragmatic, Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2383-2392.e4.	2.4	2
42	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	1.8	139
43	Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 683-690.	1.9	38
44	Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI: long-term follow-up in a surveillance cohort. <i>European Radiology</i> , 2022, 32, 5064-5074.	2.3	2
45	A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation. <i>Frontiers in Oncology</i> , 2022, 12, 818001.	1.3	7
46	Systematic review with meta-analysis: incidence of variceal hemorrhage in patients with cirrhosis undergoing transesophageal echocardiography. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1088-1098.	1.9	5
47	Reinforcement learning evaluation of treatment policies for patients with hepatitis C virus. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 63.	1.5	2
48	Reply. <i>Hepatology</i> , 2022, 76, E40-E41.	3.6	0
49	Gender, Age, Racial and Ethnic Disparities in Clinical Trial Enrollment for Primary Liver Cancer. <i>Gastroenterology</i> , 2022, 163, 14-20.e2.	0.6	7
50	Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. <i>Gastroenterology</i> , 2022, 162, 1210-1225.	0.6	17
51	Associations of Ultrasound LI-RADS Visualization Score With Examination, Sonographer, and Radiologist Factors: Retrospective Assessment in Over 10,000 Examinations. <i>American Journal of Roentgenology</i> , 2022, 218, 1010-1020.	1.0	27
52	Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2818-2825.e1.	2.4	26
53	Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. <i>Hepatology</i> , 2022, 76, 1649-1659.	3.6	18
54	Artificial intelligence and machine learning for early detection and diagnosis of colorectal cancer in sub-Saharan Africa. <i>Gut</i> , 2022, 71, 1259-1265.	6.1	22

#	ARTICLE	IF	CITATIONS
55	Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2297-2305.	3.2	8
56	Early detection of hepatocellular carcinoma: roadmap for improvement. <i>Expert Review of Anticancer Therapy</i> , 2022, , 1-12.	1.1	1
57	Insights on the Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology and Hepatology</i> , 2022, 18, 43-46.	0.2	0
58	Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. <i>Cell Metabolism</i> , 2022, 34, 969-977.e2.	7.2	163
59	Glycopeptides with Sialyl Lewis Antigen in Serum Haptoglobin as Candidate Biomarkers for Nonalcoholic Steatohepatitis Hepatocellular Carcinoma Using a Higher-Energy Collision-Induced Dissociation Parallel Reaction Monitoring-Mass Spectrometry Method. <i>ACS Omega</i> , 2022, 7, 22850-22860.	1.6	10
60	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	40
61	Ethnic Disparities in Early-Onset Gastric Cancer: A Population-Based Study in Texas and California. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1710-1719.	1.1	5
62	Persistent Disparities in Colorectal Cancer Screening: A Tell-Tale Sign for Implementing New Guidelines in Younger Adults. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1701-1709.	1.1	10
63	Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1520-1530.	2.4	23
64	Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1925-1932.e1.	2.4	46
65	Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2379-2388.e6.	2.4	7
66	Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. <i>Gut</i> , 2021, 70, gutjnl-2020-321040.	6.1	48
67	Patient Perception and Clinical Impact of Direct-to-Consumer Advertising in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 63-69.	1.1	2
68	Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. <i>Hepatology</i> , 2021, 73, 713-725.	3.6	152
69	Survival analysis among unresectable pancreatic adenocarcinoma patients undergoing endoscopic or percutaneous interventions. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 154-162.e5.	0.5	7
70	REPLY:. <i>Hepatology</i> , 2021, 73, 2618-2619.	3.6	0
71	Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan. <i>Journal of Viral Hepatitis</i> , 2021, 28, 440-444.	1.0	2
72	Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 987-995.e1.	2.4	62

#	ARTICLE	IF	CITATIONS
73	Is Colorectal Cancer in Patients Younger Than 50 Years of Age the Same Disease as in Older Patients?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 192-194.e3.	2.4	16
74	Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2021, 41, 001-008.	1.8	14
75	Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices.. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-273.	0.8	1
76	Evaluation and Management of Hepatocellular Adenomas. <i>Clinical Liver Disease</i> , 2021, 17, 57-60.	1.0	3
77	LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. <i>Abdominal Radiology</i> , 2021, 46, 3708-3716.	1.0	2
78	Expanding COVID-19 Vaccine Availability: Role for Combined Orthogonal Serology Testing (COST). <i>Vaccines</i> , 2021, 9, 376.	2.1	1
79	Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. <i>Liver Cancer</i> , 2021, 10, 407-418.	4.2	17
80	A Panel of Glycopeptides as Candidate Biomarkers for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation. <i>Journal of Proteome Research</i> , 2021, 20, 3278-3289.	1.8	23
81	Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. <i>Hepatology Communications</i> , 2021, 5, 1481-1489.	2.0	28
82	High Neutrophil Lymphocyte Ratio and Delta Neutrophil Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	8
83	Introduction to Hepatocellular Carcinoma Issue. <i>Clinical Liver Disease</i> , 2021, 17, 331-331.	1.0	0
84	16 RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA IN PATIENTS WITH INDETERMINATE (LI-RADS 3) OBSERVATIONS. <i>Gastroenterology</i> , 2021, 160, S-759-S-760.	0.6	1
85	Imaging and Biomarker Approaches to HCC Surveillance. <i>Clinical Liver Disease</i> , 2021, 17, 401-404.	1.0	4
86	Direct Acting Antiviral Therapy and Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021, 17, 414-417.	1.0	4
87	Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 422-424.	3.7	11
88	Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer. <i>Cancer Medicine</i> , 2021, 10, 4752-4767.	1.3	5
89	REPLY:. <i>Hepatology</i> , 2021, 74, 1715-1715.	3.6	0
90	Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0038821.	1.8	99

#	ARTICLE	IF	CITATIONS
91	ID: 3524123 STUDY OF COMPLIANCE, PRACTICE PATTERNS, AND BARRIERS REGARDING ESTABLISHED NATIONAL SCREENING PROGRAMS FOR BARRETT'S ESOPHAGUS AMONG GASTROENTEROLOGY PROVIDERS: SCREEN-BE. Gastrointestinal Endoscopy, 2021, 93, AB271-AB272.	0.5	0
92	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology, 2021, 160, 2572-2584.	0.6	91
93	â€œRaising HOPEâ€ Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era. Transplantation Direct, 2021, 7, e707.	0.8	9
94	State-level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology, 2021, 74, 1384-1394.	3.6	26
95	The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. Journal of the National Cancer Institute, 2021, 113, 1531-1541.	3.0	43
96	Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prevention Research, 2021, 14, 955-962.	0.7	22
97	What Survivorship Means to Liver Transplant Recipients: Qualitative Groundwork for a Survivorship Conceptual Model. Liver Transplantation, 2021, 27, 1454-1467.	1.3	12
98	Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncology, 2021, 17, 2759-2768.	1.1	16
99	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med, 2021, 2, 836-850.e10.	2.2	31
100	Health services utilization, out-of-pocket expenditure, and underinsurance among insured non-elderly cancer survivors in the United States, 2011-2015. Cancer Medicine, 2021, 10, 5513-5523.	1.3	7
101	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
102	Chronic Liver Disease and Liver Cancer. Magnetic Resonance Imaging Clinics of North America, 2021, 29, 269-278.	0.6	1
103	PRM-MS Quantitative Analysis of Isomeric N-Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma. Metabolites, 2021, 11, 563.	1.3	16
104	N-Glycosylation Patterns Correlate with Hepatocellular Carcinoma Genetic Subtypes. Molecular Cancer Research, 2021, 19, 1868-1877.	1.5	21
105	Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2021, 54, 890-901.	1.9	65
106	Clinical and Histopathologic Features Can Help Target Immunohistochemical Stain Use in the Diagnosis of Viral Esophagitis. Applied Immunohistochemistry and Molecular Morphology, 2021, Publish Ahead of Print, 713-719.	0.6	0
107	Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1063-1071.	2.3	32
108	Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States. Hepatology, 2021, 74, 2622-2632.	3.6	31

#	ARTICLE	IF	CITATIONS
109	Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice. <i>Annals of Hepatology</i> , 2021, 25, 100344.	0.6	8
110	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 6.	18.1	2,757
111	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. <i>Hepatology Communications</i> , 2021, 5, 538-547.	2.0	6
112	Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. <i>American Journal of Gastroenterology</i> , 2021, 116, 976-983.	0.2	8
113	S1108 Limited Ultrasound Visualization Is Associated with Lower Specificity During Hepatocellular Carcinoma Surveillance. <i>American Journal of Gastroenterology</i> , 2021, 116, S523-S523.	0.2	0
114	Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	1
115	The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, , .	1.8	2
116	Prevalence of Forceps Polypectomy of Non-Diminutive Polyps is Substantial but Modifiable. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	2.4	1
117	Deep learning in hepatocellular carcinoma: Current status and future perspectives. <i>World Journal of Hepatology</i> , 2021, 13, 2039-2051.	0.8	21
118	Abbreviated protocol screening MRI vs. complete protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 415-425.	1.9	57
119	Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2650-2666.	2.4	580
120	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 974-983.	2.4	16
121	Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1669-1678.	1.1	18
122	Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 242-248.e5.	2.4	57
123	Racial Disparities and Trends in Pancreatic Cancer Incidence and Mortality in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 171-178.e10.	2.4	70
124	Prevalence and clinical significance of discordant LI-RADS® observations on multiphase contrast-enhanced MRI in patients with cirrhosis. <i>Abdominal Radiology</i> , 2020, 45, 177-187.	1.0	10
125	A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 278-287.	1.1	13
126	Review article: new therapeutic interventions for advanced hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 78-89.	1.9	71

#	ARTICLE	IF	CITATIONS
127	Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient-Derived Xenograft Assays. <i>Hepatology</i> , 2020, 72, 1085-1101.	3.6	16
128	Prognostic Value of Hypochloremia in Critically Ill Patients With Decompensated Cirrhosis. <i>Critical Care Medicine</i> , 2020, 48, e1054-e1061.	0.4	13
129	Racial and Sex Disparities in Hepatocellular Carcinoma in the USA. <i>Current Hepatology Reports</i> , 2020, 19, 462-469.	0.4	26
130	Is hepatocellular carcinoma surveillance in high-risk populations effective?. <i>Hepatic Oncology</i> , 2020, 7, HEP25.	4.2	7
131	Comparison of radiofrequency and microwave ablation and identification of risk factors for primary treatment failure and local progression. <i>Clinical Imaging</i> , 2020, 67, 146-151.	0.8	4
132	Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. <i>JAMA Network Open</i> , 2020, 3, e2015626.	2.8	75
133	Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa" the case of Uganda. <i>Journal of Hepatology</i> , 2020, 73, 1273-1274.	1.8	1
134	Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis. <i>Journal of Proteome Research</i> , 2020, 19, 3452-3466.	1.8	37
135	Challenges and Approaches to Measuring Repeat Fecal Immunochemical Test for Colorectal Cancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1557-1563.	1.1	7
136	Colorectal Neoplasia among Patients with and without Human Immunodeficiency Virus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1689-1691.	1.1	5
137	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2522-2534.	1.9	20
138	Improving Cancer Outreach Effectiveness Through Targeting and Economic Assessments: Insights from a Randomized Field Experiment. <i>Journal of Marketing</i> , 2020, 84, 1-27.	7.0	37
139	Nonhospice Palliative Care Within the Treatment of End-Stage Liver Disease. <i>Hepatology</i> , 2020, 71, 2149-2159.	3.6	21
140	Patient and provider-level barriers to hepatitis C screening and linkage to care: A mixed-methods evaluation. <i>Journal of Viral Hepatitis</i> , 2020, 27, 680-689.	1.0	15
141	Addition of [18F]Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography to Cross-Sectional Imaging Improves Staging and Alters Management in Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2020, 26, 774-784.	1.3	13
142	Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 701-709.	1.9	45
143	Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 283-298.	157.7	75
144	Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. <i>Hepatology</i> , 2020, 72, 1654-1665.	3.6	93

#	ARTICLE	IF	CITATIONS
145	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. <i>Clinical Liver Disease</i> , 2020, 15, 211-212.	1.0	6
146	Prescription opioid use is common and associated with worse clinical outcomes in individuals with chronic liver disease. <i>GastroHep</i> , 2020, 2, 13-21.	0.3	0
147	Reply. <i>Gastroenterology</i> , 2020, 158, 1844.	0.6	0
148	Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. <i>Liver International</i> , 2020, 40, 947-955.	1.9	15
149	Epidemiology and surveillance for hepatocellular carcinoma: New trends. <i>Journal of Hepatology</i> , 2020, 72, 250-261.	1.8	633
150	Mice With Increased Numbers of Polyploid Hepatocytes Maintain Regenerative Capacity But Develop Fewer Hepatocellular Carcinomas Following Chronic Liver Injury. <i>Gastroenterology</i> , 2020, 158, 1698-1712.e14.	0.6	55
151	Current Knowledge and Research Priorities in the Digestive Manifestations of COVID-19. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1682-1684.	2.4	23
152	Biomarkers for the Early Detection of Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2495-2503.	1.1	67
153	Risk Factors for Cirrhosis in Contemporary Hepatology Practices—Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. <i>Gastroenterology</i> , 2020, 159, 376-377.	0.6	32
154	Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4577-4577.	0.8	3
155	Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. <i>American Journal of Gastroenterology</i> , 2020, 115, 1642-1649.	0.2	66
156	Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. <i>Hepatoma Research</i> , 2020, 2020, .	0.6	19
157	Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1210-1220.	2.3	5
158	Survival among colorectal cancer patients with a history of previous cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16146-e16146.	0.8	0
159	Abstract IA32: Liver cancer screening—How much progress have we really made?. , 2020, , .		0
160	Abstract 4340: Out-of-pocket expenditure, probability of underinsurance and health services utilization among non-elderly cancer survivors. , 2020, , .		0
161	Update on the Diagnosis and Treatment of Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2020, 16, 506-516.	0.2	4
162	Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial. <i>Hepatology</i> , 2019, 69, 121-130.	3.6	60

#	ARTICLE	IF	CITATIONS
163	Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 551-559.e1.	2.4	131
164	SAT-454-Management of hepatocellular carcinoma in a real life multinational, longitudinal, observational study (TARGET-HCC). <i>Journal of Hepatology</i> , 2019, 70, e832.	1.8	0
165	Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies. <i>Scientific Reports</i> , 2019, 9, 11580.	1.6	17
166	Efficacy and Safety of Baviximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. <i>Targeted Oncology</i> , 2019, 14, 541-550.	1.7	18
167	Regional and racial variations in the utilization of endoscopic retrograde cholangiopancreatography among pancreatic cancer patients in the United States. <i>Cancer Medicine</i> , 2019, 8, 3420-3427.	1.3	10
168	Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3428-3436.	2.0	41
169	Reply. <i>Gastroenterology</i> , 2019, 157, 901-902.	0.6	0
170	Harms of Hepatocellular Carcinoma Surveillance. <i>Current Hepatology Reports</i> , 2019, 18, 383-389.	0.4	14
171	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , 2019, 157, 1264-1278.e4.	0.6	252
172	A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019, 3, 302-310.	1.2	58
173	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
174	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1253-1263.e2.	0.6	131
175	Screening initiation with FIT or colonoscopy: Post-hoc analysis of a pragmatic, randomized trial. <i>Preventive Medicine</i> , 2019, 118, 332-335.	1.6	9
176	Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 70, 2216-2217.	3.6	7
177	Pro: Liver Transplantation Should Be Considered in Select Patients With Acute Alcoholic Hepatitis. <i>Clinical Liver Disease</i> , 2019, 13, 140-143.	1.0	5
178	AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. <i>Gastroenterology</i> , 2019, 156, 2149-2157.	0.6	90
179	Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. <i>Gastroenterology</i> , 2019, 157, 54-64.	0.6	297
180	Aspirin: Does it Have a Role for Chemoprevention of Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2019, 156, 1530-1531.	0.6	2

#	ARTICLE	IF	CITATIONS
181	Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling. <i>Nature Communications</i> , 2019, 10, 1473.	5.8	71
182	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019, 156, 1683-1692.e1.	0.6	121
183	Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease. <i>Cell</i> , 2019, 177, 608-621.e12.	13.5	167
184	Evaluation of a Multifaceted Intervention to Reduce Health Disparities in Hepatitis C Screening: A Pre-Post Analysis. <i>Hepatology</i> , 2019, 70, 40-50.	3.6	29
185	Surveillance and Diagnosis of Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2019, 13, 2-5.	1.0	27
186	<p>LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 49-69.	1.8	93
187	Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 976-987.e4.	2.4	86
188	Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1356-1363.	2.4	10
189	For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective?. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1732-1735.	2.4	5
190	Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancyâ€”A Systematic Review. <i>Gastroenterology</i> , 2019, 156, 976-986.	0.6	221
191	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1228-1238.	2.4	41
192	Outcomes associated with use of the Cancer Risk Intake System among primary care safety-net patients identified as needing colorectal cancer screening. <i>Preventive Medicine Reports</i> , 2019, 16, 101003.	0.8	4
193	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 530-532.	0.2	27
194	2264â€fHyperammonemia Secondary to an Acquired Urea Cycle Disorder in a Patient With Metastatic Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2019, 114, S1266-S1266.	0.2	1
195	Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. <i>Liver Transplantation</i> , 2019, 25, 369-379.	1.3	40
196	Hepatocellular Carcinoma Surveillance: An Effective But Complex Process. <i>Gastroenterology</i> , 2019, 156, 1215.	0.6	4
197	Hepatocellular Carcinoma: A Roadmap to Reduce Incidence and Future Burden. <i>Journal of the National Cancer Institute</i> , 2019, 111, 527-528.	3.0	7
198	The Clinical Significance of Crohn Disease Activity at Resection Margins. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 505-509.	1.2	6

#	ARTICLE	IF	CITATIONS
199	Receipt of Colonoscopy Following Diagnosis of Advanced Adenomas: An Analysis within Integrated Healthcare Delivery Systems. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 91-98.	1.1	16
200	Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 766-773.	2.4	76
201	The Gut Microbiome and Digestive Health – A New Frontier. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 215-217.	2.4	7
202	Projected increase in obesity and nonalcoholic steatohepatitis-related liver transplantation waitlist additions in the United States. <i>Hepatology</i> , 2019, 70, 487-495.	3.6	96
203	Hepatocellular Carcinoma Surveillance and Staging. <i>Molecular and Translational Medicine</i> , 2019, , 27-51.	0.4	5
204	Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000271.	1.1	18
205	Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 264-269.	4.5	50
206	Comparative Analysis of Nonalcoholic Steatohepatitis Versus Viral Hepatitis and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 322-329.	2.3	38
207	Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the United States.. <i>Journal of Clinical Oncology</i> , 2019, 37, 424-424.	0.8	0
208	Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium. <i>EGEMS (Washington, DC)</i> , 2019, 7, 37.	2.0	5
209	942 Low Incidence of Bleeding Complications in Patients With Cirrhosis Undergoing Transesophageal Echocardiography: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, S548-S548.	0.2	0
210	1000 Older Adults With Hepatocellular Carcinoma Are More Likely Than Younger Adults to Receive Curative Treatment but Have Worse Overall Survival. <i>American Journal of Gastroenterology</i> , 2019, 114, S580-S580.	0.2	0
211	Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. <i>American Journal of Gastroenterology</i> , 2018, 113, 746-754.	0.2	17
212	Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. <i>Gastroenterology</i> , 2018, 154, 1706-1718.e1.	0.6	695
213	Outcomes of simultaneous liver-kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 264-270.	0.8	8
214	Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. <i>Gastroenterology</i> , 2018, 154, 1421-1434.	0.6	88
215	Adherence to colorectal cancer screening measured as the proportion of time covered. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 323-331.e2.	0.5	17
216	Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 198-210.e2.	2.4	284

#	ARTICLE	IF	CITATIONS
217	A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 781-782.	2.4	12
218	Stereotactic ablative radiotherapy for hepatocellular carcinoma: History, current status, and opportunities. <i>Liver Transplantation</i> , 2018, 24, 420-427.	1.3	21
219	Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma. <i>Cancer</i> , 2018, 124, 743-751.	2.0	37
220	Clinicopathological Factors and Curative Treatment Receipt Differ Amongst Nonalcoholic Steatohepatitis-, Viral Hepatitis-, and Alcohol Liver Disease-Related HCC. <i>Journal of the American College of Surgeons</i> , 2018, 227, e170-e171.	0.2	1
221	2207. Barriers to HCV Treatment in a Safety-Net Hospital System. <i>Open Forum Infectious Diseases</i> , 2018, 5, S651-S652.	0.4	0
222	Decrease in Incidence of Young-Onset Colorectal Cancer Before Recent Increase. <i>Gastroenterology</i> , 2018, 155, 1716-1719.e4.	0.6	79
223	Impact of a Clinical Decision Support System on Guideline Adherence of Surveillance Recommendations for Colonoscopy After Polypectomy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1321-1328.	2.3	17
224	Staging systems of hepatocellular carcinoma: A review. <i>Indian Journal of Gastroenterology</i> , 2018, 37, 481-491.	0.7	88
225	Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. <i>Radiology</i> , 2018, 289, 816-830.	3.6	634
226	LI-RADS v2018: a Primer and Update for Clinicians. <i>Current Hepatology Reports</i> , 2018, 17, 425-433.	0.4	0
227	Reply. <i>Gastroenterology</i> , 2018, 155, 1275-1276.	0.6	0
228	Colorectal cancer incidence among Hispanics and non-Hispanic Whites in the United States. <i>Cancer Causes and Control</i> , 2018, 29, 1039-1046.	0.8	22
229	Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 127-137.	1.9	63
230	Establishing a research agenda for early-onset colorectal cancer. <i>PLoS Medicine</i> , 2018, 15, e1002577.	3.9	14
231	Testing for AFP in combination with ultrasound improves early liver cancer detection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 947-949.	1.4	26
232	Survey of Liver Transplantation Practices for Severe Acute Alcoholic Hepatitis. <i>Liver Transplantation</i> , 2018, 24, 1357-1362.	1.3	36
233	Biomarker analysis of fucosylated kininogen through depletion of lectin reactive heterophilic antibodies in hepatocellular carcinoma. <i>Journal of Immunological Methods</i> , 2018, 462, 59-64.	0.6	10
234	Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 673-681.	0.9	38

#	ARTICLE	IF	CITATIONS
235	Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Cancer Research and Treatment</i> , 2018, 50, 530-537.	1.3	23
236	Young versus Older-Onset Colorectal Cancer in a Safety Net Hospital. <i>American Journal of Gastroenterology</i> , 2018, 113, S121-S122.	0.2	0
237	Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 756-758.	2.4	1
238	Editorial: ultrasound surveillance of hepatocellular carcinoma in the 21st century - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 562-563.	1.9	1
239	Changes in the Glycosylation of Kininogen and the Development of a Kininogen-Based Algorithm for the Early Detection of HCC. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 795-803.	1.1	48
240	Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. <i>American Journal of Medicine</i> , 2017, 130, 1099-1106.e1.	0.6	99
241	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	1.1	43
242	Expansion of Criteria for Liver Transplantation in Hepatocellular Carcinoma: Better Patient Selection or a Slippery Slope?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1758-1760.	0.7	2
243	Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 296-304.	0.3	29
244	Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2017, 41, 289-293.	0.5	17
245	Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 650-655.	1.1	35
246	Reply. <i>Hepatology</i> , 2017, 66, 1002-1003.	3.6	3
247	Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2017, 152, 608-615.e4.	0.6	81
248	Direct-acting antivirals and recurrence of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2017, 23, 1099-1100.	1.3	3
249	Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 806.	3.8	98
250	Hepatocellular Carcinoma: Epidemiology, Basic Principles of Treatment, and Clinical Data. , 2017, , 149-178.		0
251	Reply. <i>Hepatology</i> , 2017, 66, 679-680.	3.6	0
252	FIB-4 and imaging for measuring fibrosis in hepatitis C virus. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 192-198.	0.8	9

#	ARTICLE	IF	CITATIONS
253	Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2017, 101, e12-e19.	0.5	5
254	Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 197-204.	2.3	31
255	Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer. <i>Cancer Cell</i> , 2017, 32, 574-589.e6.	7.7	172
256	Accuracy of Referring Provider and Endoscopist Impressions of Colonoscopy Indication. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 920-925.	2.3	1
257	Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk. <i>Preventive Medicine</i> , 2017, 102, 20-23.	1.6	10
258	Personalizing Colon Cancer Screening: Role of Age and Comorbid Conditions. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 220-226.	1.0	0
259	Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 3725-3731.	2.0	66
260	Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e101.	1.3	124
261	Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 169-177.	1.9	243
262	Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database. <i>Hepatology</i> , 2017, 65, 122-133.	3.6	82
263	An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 1196-1205.	3.6	188
264	Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 875-884.	3.6	129
265	Reasons for Lack of Diagnostic Colonoscopy After Positive Result on Fecal Immunochemical Test in a Safety-Net Health System. <i>American Journal of Medicine</i> , 2017, 130, 93.e1-93.e7.	0.6	84
266	Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. <i>Seminars in Liver Disease</i> , 2017, 37, 296-304.	1.8	29
267	CON: Hepatocellular Carcinoma Surveillance: In Need of Higher-Quality Data. <i>American Journal of Gastroenterology</i> , 2017, 112, 1634-1635.	0.2	3
268	Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. <i>BMJ: British Medical Journal</i> , 2017, 357, j1415.	2.4	514
269	Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. <i>BMC Medicine</i> , 2017, 15, 204.	2.3	46
270	Extrahepatic metastasis risk of hepatocellular carcinoma based on α -fetoprotein and tumor staging parameters at cross-sectional imaging. <i>Cancer Management and Research</i> , 2017, Volume 9, 503-511.	0.9	26

#	ARTICLE	IF	CITATIONS
271	Medical Management of Hepatocellular Carcinoma. <i>Journal of Oncology Practice</i> , 2017, 13, 356-364.	2.5	42
272	Management of hepatocellular in the United States. <i>Chinese Clinical Oncology</i> , 2017, 6, 21-21.	0.4	26
273	Patterns of Repeat Colorectal Cancer Screening and Follow-Up of Abnormal Results in an Integrated Safety-Net Health Care System. <i>Journal of Patient-centered Research and Reviews</i> , 2017, 4, 151-152.	0.6	0
274	Impact of EMR-Based Colonoscopy Results Reporting and Clinical Decision Support System on Guideline-Concordant Surveillance Recommendations. <i>American Journal of Gastroenterology</i> , 2017, 112, S143-S144.	0.2	0
275	Contained colonic perforation due to cecal retroflexion. <i>World Journal of Gastroenterology</i> , 2016, 22, 3285.	1.4	6
276	Development and Internal Validation of a Model for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 175-179.	1.1	10
277	Hepatocellular carcinoma: How can we move from racial/ethnic disparities to a model of health equity?. <i>Cancer</i> , 2016, 122, 2454-2456.	2.0	0
278	Model for end-stage liver disease exception points for treatment-responsive hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2016, 7, 97-100.	1.0	31
279	Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system. <i>Cancer</i> , 2016, 122, 456-463.	2.0	104
280	Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis. <i>American Journal of Gastroenterology</i> , 2016, 111, 967-975.	0.2	39
281	Body Composition Features Predict Overall Survival in Patients With Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e172.	1.3	18
282	228 Randomized Controlled Trial of Mailed Outreach and Patient Navigation to Increase HCC Surveillance in Patients with Cirrhosis. <i>Gastroenterology</i> , 2016, 150, S1021.	0.6	0
283	231 Practice-Level Variation in Hepatocellular Carcinoma Practices and Outcomes in the United States. <i>Gastroenterology</i> , 2016, 150, S1022.	0.6	0
284	Mo1518 HCC Surveillance Is Associated With Early Tumor Detection and Improved Survival: A Multi-Center United States Study. <i>Gastroenterology</i> , 2016, 150, S1138.	0.6	1
285	Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Potential New Challenge for Hepatocellular Carcinoma Surveillance. <i>Gastroenterology</i> , 2016, 151, 1246-1248.	0.6	3
286	Implementation of a Voice Messaging System is Associated With Improved Time-to-Treatment and Overall Survival in Patients With Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 38-46.	2.3	8
287	Controversies in criteria for liver transplantation in hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 1.	1.0	9
288	40 Racial/Ethnic Disparities in Hepatocellular Carcinoma Care Delivery. <i>Gastroenterology</i> , 2016, 150, S14.	0.6	1

#	ARTICLE	IF	CITATIONS
289	Tu1654 Therapeutic Delays are Common in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, S1157-S1158.	0.6	0
290	Development of the Parkland-UT Southwestern Colonoscopy Reporting System (CoRS) for evidence-based colon cancer surveillance recommendations. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 402-406.	2.2	12
291	Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 344-350.	1.1	106
292	The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 172-179.	0.7	48
293	Advances in Local and Systemic Therapies for Hepatocellular Cancer. <i>Current Oncology Reports</i> , 2016, 18, 9.	1.8	14
294	Treatment of Liver Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 100.	3.8	23
295	Gastric residual volume after split-dose compared with evening-before polyethylene glycol bowel preparation. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 574-580.	0.5	20
296	A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 295-300.	2.4	31
297	The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002005.	3.9	6
298	Radiation therapy for palliation of osseous metastasis from hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 204-204.	0.8	0
299	Diagnostic Delays Are Common Among Patients With Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 543-549.	2.3	40
300	Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. <i>Liver Transplantation</i> , 2015, 21, 1142-1152.	1.3	207
301	The efficacy and effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatic Oncology</i> , 2015, 2, 97-99.	4.2	2
302	Transpapillary Gallbladder Stents Can Stabilize or Improve Decompensated Cirrhosis in Patients Awaiting Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 771-777.	1.1	20
303	Post-polypectomy Guideline Adherence: Importance of Belief in Guidelines, Not Guideline Knowledge or Fear of Missed Cancer. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2937-2945.	1.1	32
304	Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 700-709.e3.	0.5	48
305	Liver Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2701.	3.8	8
306	Predictors of guideline concordance for surveillance colonoscopy recommendations in patients at a safety-net health system. <i>Cancer Causes and Control</i> , 2015, 26, 1653-1660.	0.8	8

#	ARTICLE	IF	CITATIONS
307	Racial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance. American Journal of Medicine, 2015, 128, 90.e1-90.e7.	0.6	128
308	Spirochetes as an Almost Forgotten Cause of Hepatitis. Clinical Gastroenterology and Hepatology, 2015, 13, A21-A22.	2.4	5
309	Accuracy of Ultrasound and Noninvasive Markers of Fibrosis to Identify Patients with Cirrhosis. Digestive Diseases and Sciences, 2015, 60, 1841-1847.	1.1	24
310	Role functioning is associated with survival in patients with hepatocellular carcinoma. Quality of Life Research, 2015, 24, 1669-1675.	1.5	15
311	The Reply. American Journal of Medicine, 2015, 128, e27.	0.6	0
312	Surveillance for hepatocellular carcinoma secondary to cardiogenic cirrhosis in patients with congenital heart disease. Clinical Research in Cardiology, 2015, 104, 446-449.	1.5	8
313	Periprocedural management of aspirin during colonoscopy: a survey of practice patterns in the United States. Gastrointestinal Endoscopy, 2015, 82, 895-900.	0.5	16
314	Hepatocellular Carcinoma Surveillance: Does Alpha-Fetoprotein Have a Role?. Gastroenterology, 2015, 149, 816-817.	0.6	10
315	To "or Not to " Efficacy of a Neonatal Hepatitis B Vaccination Program to Prevent Primary Liver Cancer and End-Stage Liver Disease. Gastroenterology, 2015, 148, 1073-1075.	0.6	1
316	Sa1433 Predictors of Guideline Concordance for Surveillance Colonoscopy Recommendations Among Patients in an Academic Safety-Net Health System. Gastrointestinal Endoscopy, 2015, 81, AB213-AB214.	0.5	0
317	How Can We Boost Colorectal and Hepatocellular Cancer Screening Among Underserved Populations?. Current Gastroenterology Reports, 2015, 17, 22.	1.1	9
318	Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clinical Gastroenterology and Hepatology, 2015, 13, 2140-2151.	2.4	436
319	Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma. Annals of Surgical Oncology, 2015, 22, 1075-1082.	0.7	22
320	Clinical Reminders for Hepatocellular Carcinoma Surveillance: An Early Step in a Long Journey. Clinical Gastroenterology and Hepatology, 2015, 13, 180-182.	2.4	2
321	HBV Outreach Programs Significantly Increase Knowledge and Vaccination Rates Among Asian Pacific Islanders. Journal of Community Health, 2015, 40, 619-624.	1.9	19
322	Practice Patterns and Attitudes of Primary Care Providers and Barriers to Surveillance of Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 791-798.e1.	2.4	86
323	A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 4109-4109.	0.8	1
324	Hepatocellular Carcinoma Surveillance Is Associated With Potential Harms. American Journal of Gastroenterology, 2015, 110, S891.	0.2	1

#	ARTICLE	IF	CITATIONS
325	A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 345-345.	0.8	0
326	Concordance of Referring Provider and Endoscopist Impression for Determination of Colonoscopy Indication. American Journal of Gastroenterology, 2015, 110, S982-S983.	0.2	0
327	A Primer on Effectiveness and Efficacy Trials. Clinical and Translational Gastroenterology, 2014, 5, e45.	1.3	540
328	A Primer on Predictive Models. Clinical and Translational Gastroenterology, 2014, 5, e44.	1.3	94
329	Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis. PLoS Medicine, 2014, 11, e1001624.	3.9	607
330	Letter: comparative efficacy of biological therapy in patients with ulcerative colitis - authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 1433-1434.	1.9	0
331	Improving Quality of Health Care for Patients With Cirrhosis. Gastroenterology, 2014, 147, 1204-1207.	0.6	34
332	Reply. Clinical Gastroenterology and Hepatology, 2014, 12, 2139-2140.	2.4	1
333	Importance of Determining Indication for Colonoscopy: Implications for Practice and Policy. Clinical Gastroenterology and Hepatology, 2014, 12, 1958-1963.e3.	2.4	11
334	Letter: biological drugs for inducing remission in ulcerative colitis - authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 1244-1244.	1.9	0
335	Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy. JAMA Internal Medicine, 2014, 174, 1727.	2.6	167
336	Predictive Models for Hepatocellular Carcinoma. Gastroenterology, 2014, 146, 1420-1421.	0.6	1
337	Herpes Zoster and IBD: Are We Being Brash About a Rash?. Gastroenterology, 2014, 146, 576-577.	0.6	0
338	Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome. Annals of Surgical Oncology, 2014, 21, 1287-1295.	0.7	182
339	Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 660-671.	1.9	132
340	Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America, 2014, 98, 103-118.	1.1	14
341	Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 1349-1362.	1.9	165
342	Epithelial to Mesenchymal Transition Expression Profiles as Predictive Biomarkers of Recurrence Following Resection of HCC: Implications for Current Clinical Use and Future Stratification for Systemic Therapy. Annals of Surgical Oncology, 2014, 21, 3723-3724.	0.7	6

#	ARTICLE	IF	CITATIONS
343	Hepatocellular carcinoma tumour markers: Current role and expectations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 843-853.	1.0	89
344	Improved Post-Transplant Survival in the United States for Patients with Cholangiocarcinoma After 2000. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1048-1054.	1.1	29
345	Factors That Affect Accuracy of α -Fetoprotein Test in Detection of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 870-877.	2.4	109
346	Does Surveillance for Hepatocellular Carcinoma Benefit Patients With Compensated Cirrhosis?. <i>Gastroenterology</i> , 2014, 147, 935-936.	0.6	1
347	Diagnostic Paracentesis Is Associated With Improved Survival Among Hospitalized Patients With Cirrhosis. <i>Gastroenterology</i> , 2014, 146, 858-859.	0.6	2
348	Racial Differences in the Clinical Presentation of Pediatric Eosinophilic Esophagitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 320-325.	2.0	32
349	The Changing Landscape of Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2014, 184, 574-583.	1.9	82
350	Safety Of Oral Food Challenges To Extensively Heated Egg In Children. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB209.	1.5	0
351	The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 325-334.	0.2	270
352	Screening Process Failures for Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 375-382.	2.3	34
353	Health disparities in diagnosis and treatment of hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2014, 4, 143-145.	1.0	13
354	Association of adiponectin in patatin-like phospholipase domain-containing 3 (PNPLA3) associated hepatic steatosis.. <i>Journal of Clinical Oncology</i> , 2014, 32, 184-184.	0.8	0
355	Predictors of Guideline-Consistent Colon Cancer Surveillance Recommendations After Polypectomy. <i>American Journal of Gastroenterology</i> , 2014, 109, S611.	0.2	0
356	Outcomes of IBD Care Vary Across Different Healthcare Delivery Settings. <i>American Journal of Gastroenterology</i> , 2014, 109, S501.	0.2	0
357	National Survey of Hepatitis C Treatment Practice Patterns in the Era of Direct-Acting Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, S177.	0.2	0
358	Hispanic Ethnicity is Associated With Milder Disease Severity in Crohn's Disease but not Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2014, 109, S493.	0.2	0
359	Surveillance Endoscopic Variceal Ligation Is Underutilized in Patients With Cirrhosis and Bleeding Esophageal Varices. <i>American Journal of Gastroenterology</i> , 2014, 109, S181.	0.2	0
360	Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail?. <i>American Journal of Gastroenterology</i> , 2013, 108, 425-432.	0.2	193

#	ARTICLE	IF	CITATIONS
361	Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2013, 108, 1723-1730.	0.2	233
362	A potential novel use for direct antiviral therapy. <i>Hepatology</i> , 2013, 57, 414-415.	3.6	0
363	Improving Screening for Hepatocellular Carcinoma by Incorporating Data on Levels of α -Fetoprotein, Over Time. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 437-440.	2.4	87
364	An Automated Model Using Electronic Medical Record Data Identifies Patients With Cirrhosis at High Risk for Readmission. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1335-1341.e1.	2.4	76
365	Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 1113-1118.	1.8	29
366	Improving Hepatocellular Carcinoma Screening: Applying Lessons From Colorectal Cancer Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 472-477.	2.4	49
367	Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. <i>BMJ Open</i> , 2013, 3, e003231.	0.8	8
368	Comparison of imputation methods for missing laboratory data in medicine. <i>BMJ Open</i> , 2013, 3, e002847.	0.8	284
369	Recent advances in the treatment of hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 285-292.	1.0	93
370	A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 800-806.	1.1	3
371	Surveillance for Hepatocellular Carcinoma: How Can We Do Better?. <i>American Journal of the Medical Sciences</i> , 2013, 346, 308-313.	0.4	9
372	Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 703-712.	1.9	92
373	Reply to Giannini and Trevisani. <i>American Journal of Gastroenterology</i> , 2013, 108, 1014.	0.2	0
374	Therapeutic Delays Lead to Worse Survival Among Patients With Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1101-1108.	2.3	69
375	Use of Administrative Claims Data for Identifying Patients with Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, e50-e54.	1.1	170
376	Association of the establishment of multidisciplinary (MDC) hepatocellular carcinoma (HCC) clinic with clinical outcome.. <i>Journal of Clinical Oncology</i> , 2013, 31, 332-332.	0.8	1
377	Mortality in Acute Upper Gastrointestinal Bleeding Is Uncommonly due to Persistent Hemorrhage. <i>American Journal of Gastroenterology</i> , 2013, 108, S490-S491.	0.2	1
378	Failure Rates in the Hepatocellular Carcinoma Surveillance Process. <i>Cancer Prevention Research</i> , 2012, 5, 1124-1130.	0.7	175

#	ARTICLE	IF	CITATIONS
379	Lymphocytic Esophagitis. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 828-832.	1.1	103
380	Current issues and future trends in surveillance for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 186-189.	1.0	2
381	Laparoscopic liver resection for hepatocellular carcinoma: Indications and role. <i>Clinical Liver Disease</i> , 2012, 1, 206-208.	1.0	2
382	Clinical yield of diagnostic endoscopic retrograde cholangiopancreatography in orthotopic liver transplant recipients With suspected biliary complications. <i>Liver Transplantation</i> , 2012, 18, 1479-1484.	1.3	24
383	Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1284-1290.	2.4	15
384	Su2057 Machine Learning Algorithms Outperform Conventional Regression Models in Identifying Risk Factors for Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Gastroenterology</i> , 2012, 142, S-984.	0.6	6
385	Hepatocellular Carcinoma Surveillance: All Cirrhotic Patients May Not Be Equal. <i>Gastroenterology</i> , 2012, 143, 1393-1395.	0.6	2
386	Regression of Hepatocellular Carcinoma With Right Atrial Extension After Sorafenib and Transarterial Chemoembolization. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, e83-e84.	2.4	0
387	Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 793-799.	1.1	227
388	Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2012, 57, 832-834.	1.1	2
389	Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review. <i>Journal of General Internal Medicine</i> , 2012, 27, 861-867.	1.3	245
390	Predictors of Liver Transplant Eligibility for Patients with Hepatocellular Carcinoma in a Safety Net Hospital. <i>Digestive Diseases and Sciences</i> , 2012, 57, 580-586.	1.1	15
391	Abstract 5591: A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC). , 2012, , .		1
392	Utilization of hepatocellular carcinoma surveillance in the United States.. <i>Journal of Clinical Oncology</i> , 2012, 30, 174-174.	0.8	1
393	Pathologic complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?. <i>Journal of Clinical Oncology</i> , 2012, 30, 597-597.	0.8	1
394	Pathological complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?. <i>Journal of Clinical Oncology</i> , 2012, 30, e14165-e14165.	0.8	4
395	Predictors of Accuracy of Non-Invasive Markers of Hepatic Fibrosis. <i>American Journal of Gastroenterology</i> , 2012, 107, S199-S200.	0.2	0
396	Clinical Presentation and Outcomes of Patients With Cirrhosis and Hemorrhagic Ascites. <i>Gastroenterology</i> , 2011, 140, S-957.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Is MRCP equivalent to ERCP for diagnosing biliary obstruction in orthotopic liver transplant recipients? A meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 955-962.	0.5	58
398	Factors associated with esophageal stricture formation after endoscopic mucosal resection for neoplastic Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 753-760.	0.5	67
399	Patient Involvement in Healthcare is Associated With Higher Rates of Surveillance for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 727-732.	1.1	83
400	Use of the AST to platelet ratio index in HCV/HIV coinfected patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 566-577.	1.9	30
401	Impact of CD4+ T-cell count on the performance of non-invasive fibrosis markers in HIV-HCV patients: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1174-1175.	1.9	0
402	Detection and management of latent tuberculosis in liver transplant patients. <i>Liver Transplantation</i> , 2011, 17, 306-314.	1.3	56
403	Recent advances in the treatment of hepatocellular carcinoma. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 189-195.	1.0	79
404	The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 625-633.	1.9	31
405	Meta-analysis: retreatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 969-983.	1.9	21
406	Meta-analysis: insulin sensitizers for the treatment of nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1211-1221.	1.9	139
407	A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 280-288.e1.	2.4	328
408	W1424: Factors Associated With Esophageal Stricture Development Following Endoscopic Mucosal Resection for Neoplastic Barrett's Esophagus. <i>Gastrointestinal Endoscopy</i> , 2010, 71, AB324-AB325.	0.5	1
409	Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 37-47.	1.9	703
410	Role of liver transplantation in the treatment of cholangiocarcinoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 491-502.	1.1	11
411	Impact of Capsule Endoscopy on Clinical Management: A Single Center Experience. <i>American Journal of Gastroenterology</i> , 2009, 104, S113.	0.2	0
412	Roseomonas Infection Associated With a Left Ventricular Assist Device. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 963-965.	1.0	9
413	A Novel Member of the Tob Family of Proteins Controls Sexual Fate in <i>Caenorhabditis elegans</i> Germ Cells. <i>Developmental Biology</i> , 2000, 217, 77-90.	0.9	72
414	A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
415	Improving Cancer Outreach Effectiveness Through Targeting and Economic Assessments: Insights from a Randomized Field Experiment. SSRN Electronic Journal, 0, , .	0.4	1
416	Screening for Hepatocellular Carcinoma in Viral Liver Disease: Is Ultrasound Enough?. , 0, , 9-12.		0
417	Survival of cancer survivors with a new pancreatic cancer diagnosis. Cancer Medicine, 0, , .	1.3	3
418	<scp>Real-world</scp> effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in <scp>US</scp> clinical practice. Cancer Reports, 0, , .	0.6	2